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 Relative Hypoleptinemia in Poorly Controlled Patients 
with Type 1 Diabetes 
years. We excluded patients with obesity (class I –
 III) in order to eliminate those who had clear insu-
lin resistance associated to T1DM. All subjects 
followed a balanced nutritional scheme and kept a 
diary to quantify compliance to the diet program 
(number of days of free food intake). After three 
months we assessed insulin resistance by evaluat-
ing clinical signs and symptoms (acanthosis nigri-
cans, waist circumference, BMI, blood pressure), 
biochemical parameters (HbA1c, lipids, uricemia), 
adipocytokine levels (Apn, Lep and A / L ratio) and 
endothelial dysfunction markers (microalbuminu-
ria and PCR). Residual   -cell function was deter-
mined by measuring urinary (UCP) and serum 
C-peptide levels evaluation before and after a glu-
cagon test (0  and 6  ). The Institutional ethics 
committee approved the study and all participants 
signed informed consent. Data are presented as 
mean  ±  SD. The Mann – Whitney U test was used to 
compare groups. A linear logistic regression model 
was applied to determine the relationship between 
dependent (HbA1c) and independent variables 
(IR, Waist, BMI, CPU, 0  and 6  C-peptide, Adp, Lep, 
A / L ratio, number of days of non-regular diet). 
 Results 
 & 
 Patients were divided in two groups based on 
BMI: BMI   <  26  kg / m 2 (18 / 25, Group A) and BMI 
>26  kg / m 2 (7 / 25, Group B). Lep values were sig-
niﬁ cantly higher (9.4  ±  6.4  ng / ml vs. 3.3  ±  2.9  ng / ml; 
p  =  0.005) and A / L ratio signiﬁ cantly lower (2.4  ±  1 
vs. 18.6  ±  25.9; p  <  0,001) in group B. No signiﬁ cant 
differences were found for other parameters 
examined, suggesting that glycemic control and 
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 Introduction 
 & 
 Insulin sensitivity is strictly related to body fat 
mass. Several studies in type 2 diabetes (T2DM) 
demonstrated that insulin regulates leptin (Lep) 
per se, regardless of adiposity  [1,  2] . On the con-
trary, plasma adiponectin (Apn), another mole-
cule speciﬁ cally secreted from adipocytes, is 
negatively correlated with insulin resistance and 
body mass index (BMI)  [3,  4] . Unlike the HOMA-
IR, an index of insulin resistance, the adiponectin /
 leptin ratio (A / L ratio) is not inﬂ uenced by fasting 
glucose plasma levels and could be considered a 
sensitive and reliable marker of insulin resist-
ance in T2DM. Type 1 diabetes mellitus (T1DM) 
is an organ-speciﬁ c autoimmune disease result-
ing from the T-cell mediated destruction of pan-
creatic   -cells, though glycemic control is also 
related to reduction in insulin sensitivity. 
Although it is well known that adipocytokines, 
principally Lep, may inﬂ uence T-cell function 
 [5,  6] , their role in insulin sensitivity has not been 
sufﬁ ciently investigated in Type 1 diabetes. 
 Material and Methods 
 & 
 The aim of this prospective study was to evaluate 
whether insulin sensitivity could inﬂ uence glyc-
emic control in patients with T1DM after 5 years 
from the onset. The patients were classiﬁ ed, in 
accordance to ADA criteria, as T1DM because of 
acute onset of symptoms, DKA and positive pan-
creatic   -cell auto-antibodies (anti-GAD and / or 
anti-IA2). We studied 25 consecutive (20 males, 5 
females) non-obese (BMI 23.66  ±  3.49  Kg / m 2 ; 
range 19 – 29.5) T1DM subjects, aged 22  ±  9.21 
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residual   -cell function did not differ in normal weight patients 
(group A) and overweight patients (group B) ( Table 1 ). Using a 
multiple linear logistic regression model to evaluate which of the 
independent variables could inﬂ uence HbA1c, we found that high 
HbA1c values correlated with increased BMI    =  0.73; p  =  0.034), IR 
(   =  0.74; p  =  0.001), number of days of non-regular diet (   =  0.40; 
p  =  0.015) and reduced Lep levels (   =   −  0.71; p  =  0.004). A / L ratio 
was signiﬁ cantly lower in group B (overweight), as Apn levels 
(related to insulin resistance) did not differ in the two groups, and 
only Lep values (obviously higher in group B) markedly inﬂ uenced 
A / L ratio. Thus it is not possible to assert that these patients are 
less insulin sensible only on the basis of A / L ratio. 
 Conclusions 
 & 
 In conclusion, we have found an association between poor com-
pliance to diet and elevated HbA1c with relative hypoleptinemia 
in nonobese patients with T1DM, similar to patients affected by 
the metabolic syndrome  [7] . Hypoleptinemia could accelerate 
lipogenesis and reduce FFA oxidation in muscle and liver, thus 
decreasing insulin sensitivity in these tissues. From our study, 
we hypothesize that the transient lipotoxicity is able to inﬂ u-
ence glycemic control and HbA1c values in Type 1 diabetes. 
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 Table 1  Clinical and metabolic parameters in Type 1 diabetic patients with   <  26  Kg / m 2 (Group A) and   >  26  Kg / m 2 (Group B) BMI 
  Group A 
BMI  <  26  Kg / m 2 
n  =  18 
 Group B 
BMI   >  26  Kg / m 2 
n  =  7 
 
  Media  Dev. St.  Media  Dev. St.  P  †  
 Diagnosis of T1DM (years)  21.22  8.9  24.71  10.22  0.389 
 BMI (kg / m 2 )  22.05  2.64  27.78  1.25  – 
 Waist Circumference (cm)  81.42  8.36  95.42  6.21   <  0.001  *  
 Systolic blood pressure  113.06  7.88  120  13.22  0.297 
 Diastolic blood pressure  72.50  9.43  75.71  9.32  0.38 
 Leptin (ng / ml)  3.36  2.97  9.40  6.42  0.005  *  
 Adiponectin (ng / ml)  24.32  10.24  17.70  4.25  0.097 
 Adiponectin / leptin ratio  18.64  25.96  2.4  1.07   <  0.001  *  
 Total cholesterol (mg / dl)  165.16  35.88  170.42  17.75  0.574 
 HDL cholesterol (mg / dl)  47.03  12.3  45.54  11.52  0.976 
 Triglycerides (mg / dl)  86.27  35.50  95.28  37.45  0.657 
 LDL cholesterol (mg / dl)  100.83  34.83  105.97  20.97  0.458 
 HbA1c (  % )  7.33  1.19  7.44  1.50  0.790 
 Insulin Requirement (U / Kg / BW)  0.50  0.33  0.52  0.15  0.357 
 CPU (  g / 24 h)  26.05  23.33  30.65  17.83  0.458 
 Basal C-peptide (nmol / l)  0.61  1.08  0.53  0.58  0.976 
 6  C-peptide (nmol / l)  0.66  0.4  0.78  0.80  0.976 
 Delta C-peptide (0  – 6  )  0.13  3.13  0.77  1.8  0.244 
 Serum creatinine (mg / dl)  0.84  0.23  0.96  0.10  0.178 
 Microalbuminuria (mg / l)  10.14  13.74  38.34  65.73  0.745 
 C-Reactive Protein (mg / l)  0.89  1.03  1.44  1.39  0.178 
  n   %  n   %  p  † †  
 Sex 
 Males  14  77.8  1  14.3  0.656 
 Females  4  22.2  6  85.7  
 DM family history  10  55.5  6  85.7  0.355 
 Obesity family history  8  44  5  71  0.378 
 Acanthosis nigricans  1  5  1  14  0.490 
  †  Mann – Whitney Test;   † †   2 Test;   *  Signiﬁ cant values when  p  <  0.05 
